Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1999 1
2002 2
2003 1
2006 1
2007 1
2010 1
2012 2
2013 3
2014 2
2016 1
2017 1
2019 1
2020 4
2021 12
2022 5
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Schneeweiss A, et al. Among authors: mcnally v. Ann Oncol. 2013 Sep;24(9):2278-84. doi: 10.1093/annonc/mdt182. Epub 2013 May 22. Ann Oncol. 2013. PMID: 23704196 Free article. Clinical Trial.
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Felip E, Altorki N, Zhou C, Vallières E, Martínez-Martí A, Rittmeyer A, Chella A, Reck M, Goloborodko O, Huang M, Belleli R, McNally V, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA. Felip E, et al. Among authors: mcnally v. Ann Oncol. 2023 Oct;34(10):907-919. doi: 10.1016/j.annonc.2023.07.001. Epub 2023 Jul 17. Ann Oncol. 2023. PMID: 37467930 Free article. Clinical Trial.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P. Gianni L, et al. Among authors: mcnally v. Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11. Lancet Oncol. 2016. PMID: 27179402 Clinical Trial.
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, Yan Y, Huang KC, Uyei A, McNally V, McArthur GA, Ascierto PA. Gutzmer R, et al. Among authors: mcnally v. Lancet. 2020 Jun 13;395(10240):1835-1844. doi: 10.1016/S0140-6736(20)30934-X. Lancet. 2020. PMID: 32534646 Clinical Trial.
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Zhou C, Srivastava MK, Xu H, Felip E, Wakelee H, Altorki N, Reck M, Liersch R, Kryzhanivska A, Oizumi S, Tanaka H, Hamm J, McCune SL, Bennett E, Gitlitz B, McNally V, Ballinger M, McCleland M, Zou W, Das Thakur M, Novello S. Zhou C, et al. Among authors: mcnally v. J Immunother Cancer. 2023 Oct;11(10):e007047. doi: 10.1136/jitc-2023-007047. J Immunother Cancer. 2023. PMID: 37903590 Free PMC article. Clinical Trial.
Recommended Adult Immunization Schedule, United States, 2022.
Murthy N, Wodi AP, Bernstein H, Ault KA; Advisory Committee on Immunization Practices†; Advisory Committee on Immunization Practices. Murthy N, et al. Ann Intern Med. 2022 Mar;175(3):432-443. doi: 10.7326/M22-0036. Epub 2022 Feb 18. Ann Intern Med. 2022. PMID: 35175828 Free article. No abstract available.
Recommended Adult Immunization Schedule, United States, 2021.
Freedman MS, Bernstein H, Ault KA; Advisory Committee on Immunization Practices. Freedman MS, et al. Ann Intern Med. 2021 Mar;174(3):374-384. doi: 10.7326/M20-8080. Epub 2021 Feb 11. Ann Intern Med. 2021. PMID: 33571011 Free article. No abstract available.
Recommended Adult Immunization Schedule, United States, 2023.
Murthy N, Wodi AP, Cineas S, Ault KA; Advisory Committee on Immunization Practices. Murthy N, et al. Ann Intern Med. 2023 Mar;176(3):367-380. doi: 10.7326/M23-0041. Epub 2023 Feb 10. Ann Intern Med. 2023. PMID: 36757885 Free article. No abstract available.
Recommended Adult Immunization Schedule, United States, 2024.
Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S; Advisory Committee on Immunization Practices. Murthy N, et al. Among authors: mcnally vv. Ann Intern Med. 2024 Feb;177(2):221-237. doi: 10.7326/M23-3269. Epub 2024 Jan 12. Ann Intern Med. 2024. PMID: 38206843 Free article. No abstract available.
Recommended Adult Immunization Schedule, United States, 2020.
Freedman M, Kroger A, Hunter P, Ault KA; Advisory Committee on Immunization Practices. Freedman M, et al. Ann Intern Med. 2020 Mar 3;172(5):337-347. doi: 10.7326/M20-0046. Epub 2020 Feb 4. Ann Intern Med. 2020. PMID: 32016359 Free PMC article. No abstract available.
46 results